Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: no observation of increased radiation-induced acute, or late effects

被引:47
作者
Bremer, M
Klopper, K
Yamini, P
Bendix-Waltes, R
Dork, T
Karstens, JH
机构
[1] Hannover Med Sch, Dept Radiat Oncol, D-30625 Hannover, Germany
[2] Hannover Med Sch, Dept Obstet & Gynecol, D-30625 Hannover, Germany
关键词
ataxia-telangiectasia; A-T heterozygosity; breast cancer; radiation sensitivity;
D O I
10.1016/j.radonc.2003.08.004
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: Reports on increased late subcutaneous toxicity after radiation therapy (RT) in breast cancer patients carrying ATM gene mutations has raised concerns about RT as part of the management in these patients. The impact of ataxia-telangiectasia (A-T) heterozygosity on clinical radiosensitivity remains a matter of debate while clinical data are scarce. Patients and methods: Between September 1995 and December 2002 genomic DNA samples were collected from 1100 unselected breast cancer patients receiving adjuvant radiotherapy at our department. Using mutation-specific assays, we screened for frequent ATM gene mutations. Analysis of acute and late radiation-related toxicity for skin and subcutaneous normal tissue was performed in patients identified as A-T heterozygotes applying common toxicity criteria (CTC) and LENT/SOMA (late effects on normal tissue/subjective objective management analytic) scoring criteria, respectively. Results: Eleven patients were identified to be heterozygous for a pathogenic ATM gene mutation. Ten patients had received at least one course of RT. Median follow-up after completion of radiotherapy was 5.1 years (range 1.7-7.2). There was no evidence of increased radiation-induced acute or late skin or subcutaneous reactions in patients treated with linac-based RT. One patient failed distantly and was subsequently irradiated at four different sites for bone and brain metastases. Local relapse occurred in the single patient who had declined adjuvant RT following breast conservative therapy. Conclusions: Our results do not provide evidence for a relative contraindication to adjuvant RT in A-T heterozygous breast cancer patients. Due to their increased cellular radiosensitivity, these patients may differentially benefit from RT and qualify for dose and volume reduction trials. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:155 / 160
页数:6
相关论文
共 34 条
[21]   Characterization of ATM gene mutations in 66 ataxia telangiectasia families [J].
Sandoval, N ;
Platzer, M ;
Rosenthal, A ;
Dörk, T ;
Bendix, R ;
Skawran, B ;
Stuhrmann, M ;
Wegner, RD ;
Sperling, K ;
Banin, S ;
Shiloh, Y ;
Baumer, A ;
Bernthaler, U ;
Sennefelder, H ;
Brohm, M ;
Weber, BHF ;
Schindler, D .
HUMAN MOLECULAR GENETICS, 1999, 8 (01) :69-79
[22]   A SINGLE ATAXIA-TELANGIECTASIA GENE WITH A PRODUCT SIMILAR TO PI-3 KINASE [J].
SAVITSKY, K ;
BARSHIRA, A ;
GILAD, S ;
ROTMAN, G ;
ZIV, Y ;
VANAGAITE, L ;
TAGLE, DA ;
SMITH, S ;
UZIEL, T ;
SFEZ, S ;
ASHKENAZI, M ;
PECKER, I ;
FRYDMAN, M ;
HARNIK, R ;
PATANJALI, SR ;
SIMMONS, A ;
CLINES, GA ;
SARTIEL, A ;
GATTI, RA ;
CHESSA, L ;
SANAL, O ;
LAVIN, MF ;
JASPERS, NGJ ;
MALCOLM, A ;
TAYLOR, R ;
ARLETT, CF ;
MIKI, T ;
WEISSMAN, SM ;
LOVETT, M ;
COLLINS, FS ;
SHILOH, Y .
SCIENCE, 1995, 268 (5218) :1749-1753
[23]   Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer [J].
Scott, SP ;
Bendix, R ;
Chen, P ;
Clark, R ;
Dörk, T ;
Lavin, MF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (02) :925-930
[24]   ATM and related protein kinases: Safeguarding genome integrity [J].
Shiloh, Y .
NATURE REVIEWS CANCER, 2003, 3 (03) :155-168
[25]   Mutagen sensitivity of human lymphoblastoid cells with a BRCA1 mutation in comparison to ataxia telangiectasia heterozygote cells [J].
Speit, G ;
Trenz, K ;
Schütz, P ;
Bendix, R ;
Dörk, T .
CYTOGENETICS AND CELL GENETICS, 2000, 91 (1-4) :261-266
[26]   ATM mutations and phenotypes in ataxia-telangiectasia families in the British Isles:: Expression of mutant ATM and the risk of leukemia, lymphoma, and breast cancer [J].
Stankovic, T ;
Kidd, AMJ ;
Sutcliffe, A ;
McGuire, GM ;
Robinson, P ;
Weber, P ;
Bedenham, T ;
Bradwell, AR ;
Easton, DF ;
Lennox, GG ;
Haites, N ;
Byrd, PJ ;
Taylor, AMR .
AMERICAN JOURNAL OF HUMAN GENETICS, 1998, 62 (02) :334-345
[27]   Outcomes of adjuvant radiation therapy for breast cancer in women with ataxia-telangiectasia mutations [J].
Su, Y ;
Swift, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 286 (18) :2233-2234
[28]   INCIDENCE OF CANCER IN 161 FAMILIES AFFECTED BY ATAXIA-TELANGIECTASIA [J].
SWIFT, M ;
MORRELL, D ;
MASSEY, RB ;
CHASE, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (26) :1831-1836
[29]  
Thorstenson YR, 2003, CANCER RES, V63, P3325
[30]  
Varghese S, 1999, RADIAT ONCOL INVESTI, V7, P231, DOI 10.1002/(SICI)1520-6823(1999)7:4<231::AID-ROI4>3.0.CO